Advertisement
OVID vs VIR
Which Stock Would AI Choose? Ovid Therapeutics (OVID) vs. Vir Biotechnology (VIR) Stock Comparison
Key Takeaways
- OVID and VIR are both clinical-stage biotechnology companies, but they pursue sharply different markets: OVID targets rare epilepsies and neuropsychiatric brain disorders, while VIR is split between chronic hepatitis delta (CHD) and a growing oncology franchise.
- VIR has a meaningfully larger market capitalization, a deeper cash position (roughly $901 million plus a recent $90 million collaboration payment), and a fuller near-term catalyst calendar than OVID.
- OVID has delivered stronger recent share-price momentum — more than doubling over the past year — driven by a repositioned pipeline and a series of analyst price-target increases.
- Tickeron AI Verdict: Based on trend consistency, financial runway, catalyst breadth, and partnership validation, Tickeron's AI currently leans toward VIR as the more favorably positioned of the two.
- You can explore more detail on each company's major news and today's price moves: OVID Major News and OVID Today's Price Move, plus VIR Major News and VIR Today's Price Move.
- For a broader look at how automated strategies are reading the market right now, explore Trending AI Robots.
Introduction
Comparing two clinical-stage biotechnology names such as Ovid Therapeutics (OVID) and Vir Biotechnology (VIR) offers a useful lens on how investors weigh pipeline quality, catalysts, and balance-sheet strength against pure share-price momentum. Both companies are pre-profitability developers of novel medicines, yet they operate in different disease areas and at different stages of scale. This stock comparison is most relevant to growth-oriented and event-driven investors who track biotech readouts, as well as to traders evaluating relative performance and market positioning in a sector where sentiment can shift rapidly on clinical data.
OVID Overview and Recent Performance
OVID, or Ovid Therapeutics Inc., is a biopharmaceutical company developing small-molecule medicines for brain disorders, with a focus on epilepsies and seizure-related neurological conditions. In recent weeks, the company has pivoted its pipeline toward its GABA-aminotransferase inhibitor OV329 and a class of KCC2 activator candidates, including OV350 and OV4071, which target neurological and psychiatric conditions such as Parkinson's disease psychosis.
The stock has been one of the more notable momentum stories in its segment, appreciating well over 100% on a one-year basis while trading in a wide range between roughly $1.12 and $3.11. Sentiment has been supported by positive early-stage data, inclusion in the S&P Biotechnology Select Industry Index, an extended cash runway, and a flurry of analyst activity — including price-target increases from firms such as Wedbush, HC Wainwright, Guggenheim, UBS, and Roth Capital. A leadership change, including the appointment of a new chief financial officer, has added to the narrative. As an early-stage developer with modest revenue, however, OVID remains sensitive to clinical and financing outcomes.
VIR Overview and Recent Performance
VIR, or Vir Biotechnology Inc., is a clinical-stage biopharmaceutical company focused on serious infectious diseases and cancer. Its lead program combines tobevibart and elebsiran for chronic hepatitis delta (CHD), a severe viral liver disease, with topline data from the Phase 3 ECLIPSE-1 trial expected in the fourth quarter of 2026. The company is also building an oncology franchise around dual-masked T-cell engagers, including VIR-5500 (prostate cancer), VIR-5818 (HER2), and VIR-5525 (EGFR).
Recent market activity has been shaped by several catalysts: FDA Fast Track designation for VIR-5500 in late-line metastatic castration-resistant prostate cancer, a global collaboration with Astellas, and a new research collaboration with Gilead validating its PRO-XTEN masking platform. Vir reported a narrowed third-quarter net loss and ended the period with roughly $901 million in cash, with runway guided into the second half of 2028. The shares have gained roughly 90% year to date, reflecting a broader catalyst lineup despite the inherent binary risk of upcoming clinical readouts.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies from a much larger universe of AI-driven bots that collectively monitor thousands of tickers. Rather than listing every available bot, this section surfaces only those whose performance, risk profile, and strategy are best aligned with current market conditions. These bots span a wide variety of trading styles — from short-term swing and momentum approaches to longer-horizon trend-following systems — each with its own timeframe, statistics, and set of securities. Exploring the page can help traders understand how algorithmic models are currently positioning across names like OVID and VIR, and which strategies are resonating in today's environment. Visit Trending AI Robots to review the latest selections.
Head-to-Head Comparison
The clearest contrast between OVID and VIR is one of scale and diversification. VIR operates across two distinct therapeutic pillars — a late-stage CHD program and an oncology portfolio validated by partnerships with Astellas and Gilead — and holds a much larger cash balance. OVID, by comparison, is a smaller, more concentrated developer centered on a neurology pipeline with earlier-stage assets and a lower market capitalization.
On growth drivers, VIR benefits from multiple near-term catalysts, including the ECLIPSE readouts and advancing oncology trials, while OVID's value proposition rests more heavily on early-stage data and clinical progress that is further from commercialization. In terms of recent momentum, OVID has shown sharper percentage gains, but VIR's moves have been supported by a denser sequence of corporate and regulatory milestones. Risk factors also differ: OVID faces concentration risk around a narrow pipeline, while VIR carries binary event risk tied to its Phase 3 hepatitis delta data. Overall, VIR offers broader diversification and financial depth, whereas OVID presents higher volatility with a more concentrated upside thesis.
Tickeron AI Verdict
Weighing trend consistency, catalyst density, balance-sheet strength, and partnership validation, Tickeron's AI currently tilts toward VIR as the more favorably positioned of the two. The company's combination of a late-stage program nearing key readouts, a validated oncology platform, and a cash runway extending into 2028 provides a comparatively stable and diversified foundation. While OVID has demonstrated stronger recent price momentum, its earlier-stage pipeline and narrower catalyst set introduce greater variability. This assessment reflects observable market factors and relative positioning rather than a prediction of future returns, and it should be interpreted as a probabilistic read on current conditions rather than a definitive outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OVID is a Hold and VIR is a Hold.
OVID's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for OVID turned positive on October 21, 2026. Looking at past instances where OVID's MACD turned positive, the stock continued to rise in 48 of 52 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OVID's RSI Indicator exited the oversold zone, 17 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on OVID as a result. In 76 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
OVID moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for OVID crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +14.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in 207 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
OVID broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for OVID entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.652) is normal, around the industry mean (3.498). P/E Ratio (-13.571) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VIR in upward trend: price rose above 50-day moving average on October 26, 2026
VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 68 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for VIR just turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 32 of 41 cases over the following month. The odds of a continued upward trend are 78%.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 130 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for VIR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 27 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.498). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
OVID | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 41 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 17 Undervalued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 96 | |
PRICE GROWTH RATING 1..100 | 37 | 35 | |
P/E GROWTH RATING 1..100 | 76 | 81 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OVID's Valuation (17) in the Pharmaceuticals Major industry is in the same range as VIR (19) in the null industry. This means that OVID’s stock grew similarly to VIR’s over the last 12 months.
OVID's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as VIR (100) in the null industry. This means that OVID’s stock grew similarly to VIR’s over the last 12 months.
OVID's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as VIR (96) in the null industry. This means that OVID’s stock grew similarly to VIR’s over the last 12 months.
VIR's Price Growth Rating (35) in the null industry is in the same range as OVID (37) in the Pharmaceuticals Major industry. This means that VIR’s stock grew similarly to OVID’s over the last 12 months.
OVID's P/E Growth Rating (76) in the Pharmaceuticals Major industry is in the same range as VIR (81) in the null industry. This means that OVID’s stock grew similarly to VIR’s over the last 12 months.
| OVID | VIR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 74% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 80% |
| Advances ODDS (%) | 8 days ago 77% | 3 days ago 76% |
| Declines ODDS (%) | 10 days ago 85% | 10 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
OVID’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
- OVID’s FA Score: 1 green, 4 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
OVID’s TA Score shows that 6 TA indicator(s) are bullish while VIR’s TA Score has 6 bullish TA indicator(s).
- OVID’s TA Score: 6 bullish, 4 bearish.
- VIR’s TA Score: 6 bullish, 4 bearish.
Price Growth
OVID (@Biotechnology) experienced а +16.67% price change this week, while VIR (@Biotechnology) price change was +17.20% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
OVID is expected to report earnings on Nov 11, 2026.
VIR is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
OVID and
Correlation & Price change
A.I.dvisor indicates that over the last year, OVID has been loosely correlated with CLDX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if OVID jumps, then CLDX could also see price increases.
| Ticker / NAME | Correlation To OVID | 1D Price Change % | ||
|---|---|---|---|---|
| OVID | 100% | -1.75% | ||
| CLDX - OVID | 42% Loosely correlated | -1.89% | ||
| SLDB - OVID | 42% Loosely correlated | +2.14% | ||
| SANA - OVID | 40% Loosely correlated | -1.42% | ||
| VIR - OVID | 40% Loosely correlated | -3.63% | ||
| CADL - OVID | 40% Loosely correlated | -1.48% | ||
More | ||||
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | -3.63% | ||
| BEAM - VIR | 54% Loosely correlated | -6.92% | ||
| EDIT - VIR | 54% Loosely correlated | -8.91% | ||
| DNLI - VIR | 52% Loosely correlated | -2.36% | ||
| SLDB - VIR | 52% Loosely correlated | +2.14% | ||
| BCYC - VIR | 51% Loosely correlated | -2.12% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IPB | 24.92 | N/A | N/A |
| Merrill Lynch Depositor | |||
| BKWO | 37.72 | N/A | N/A |
| BNY Mellon Womens's Opportunities ETF | |||
| DLS | 84.72 | -0.14 | -0.16% |
| WisdomTree International SmallCap Dividend Fund (DLS) | |||
| APMU | 24.72 | -0.06 | -0.22% |
| ActivePassive Intermediate Municipal Bond ETF (APMU) | |||
| RDFI | 21.72 | -0.37 | -1.68% |
| Rareview Dynamic Fixed Income ETF (RDFI) | |||